Poor survival in prostate cancer patients with primary refractoriness to docetaxel.
about
Docetaxel Rechallenge in a Heavily Pretreated Patient With Castration-Resistant Prostate Cancer: A Case Report and Review of LiteratureCholesterol biosynthesis inhibitor RO 48-8071 suppresses growth of hormone-dependent and castration-resistant prostate cancer cellsLack of Cumulative Toxicity Associated With Cabazitaxel Use in Prostate Cancer.Carboplatin plus etoposide in heavily pretreated castration-resistant prostate cancer patients.Targeting AXL overcomes resistance to docetaxel therapy in advanced prostate cancer.The Influence of Prednisone on the Efficacy of Cabazitaxel in Men with Metastatic Castration-Resistant Prostate Cancer.Is in vitro-acquired resistance to enzalutamide a useful model?Contemporary molecular tests for prognosis and treatment guidance for castration-resistant prostate cancer.
P2860
Q26750735-ED5A0B77-6849-4DD1-B741-2F00B1D519C2Q28829206-71101D48-543B-4BD0-BE51-62C32668001FQ38696205-EE2954F1-32DC-4EC8-A0BC-4D2C5E4C0D00Q39155556-582F008F-7546-47EB-8C3C-2F0C077D23D0Q41093141-1F9D41BE-4608-4E70-ADAD-02FC4E1865FFQ41721844-C35E6612-FA08-454F-9DE3-787E5652E167Q48658920-744364C0-B117-4D22-874E-490BEE3BADFAQ51465026-AC9F4A65-483B-42A9-8545-0E2E3CB8721B
P2860
Poor survival in prostate cancer patients with primary refractoriness to docetaxel.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
Poor survival in prostate cancer patients with primary refractoriness to docetaxel.
@en
Poor survival in prostate cancer patients with primary refractoriness to docetaxel.
@nl
type
label
Poor survival in prostate cancer patients with primary refractoriness to docetaxel.
@en
Poor survival in prostate cancer patients with primary refractoriness to docetaxel.
@nl
prefLabel
Poor survival in prostate cancer patients with primary refractoriness to docetaxel.
@en
Poor survival in prostate cancer patients with primary refractoriness to docetaxel.
@nl
P50
P1433
P1476
Poor survival in prostate cancer patients with primary refractoriness to docetaxel.
@en
P2093
Giuseppe Di Lorenzo
Sergio Bracarda
P304
P356
10.1016/J.EURURO.2013.10.037
P407
P577
2013-11-06T00:00:00Z